IDC441

IDC441 is an investigational antibody-drug conjugate (ADC) being developed by Prestige Biopharma for the treatment of solid tumors. As part of the company's innovative drug pipeline, IDC441 is designed to utilize a monoclonal antibody to selectively target tumor-associated antigens and deliver a potent cytotoxic payload directly to cancer cells. This targeted delivery mechanism is intended to maximize therapeutic efficacy while minimizing the systemic toxicity often associated with conventional chemotherapy. IDC441 is currently in the preclinical stage of development, with its specific molecular target and payload details remaining undisclosed by the developer.